REPL
1 tracked call · 1 long · 0 short · last 90d: 1L/0S
first called by Adam Feuerstein ✡️ 1mo ago
LONG1mo ago
“$REPL RP1 will be reviewed in "late July," per the company this morning.”Adam Feuerstein ✡️
FDA AdCom for REPL's RP1 oncolytic therapy confirmed for late July, just days ahead of an August 2 approval decision for advanced melanoma.
REPLLONG@ $11.62
$11.27-3.03%
since call Jun 26
peak +6.1%